BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 20425451)

  • 1. Genetic abnormalities in acute myelogenous leukemia with normal cytogenetics.
    Wald D; Vermaat JM; Peleg G; Tse W
    Curr Hematol Malig Rep; 2008 Apr; 3(2):83-8. PubMed ID: 20425451
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular prognostic markers for adult acute myeloid leukemia with normal cytogenetics.
    Gregory TK; Wald D; Chen Y; Vermaat JM; Xiong Y; Tse W
    J Hematol Oncol; 2009 Jun; 2():23. PubMed ID: 19490647
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic importance of MN1 transcript levels, and biologic insights from MN1-associated gene and microRNA expression signatures in cytogenetically normal acute myeloid leukemia: a cancer and leukemia group B study.
    Langer C; Marcucci G; Holland KB; Radmacher MD; Maharry K; Paschka P; Whitman SP; Mrózek K; Baldus CD; Vij R; Powell BL; Carroll AJ; Kolitz JE; Caligiuri MA; Larson RA; Bloomfield CD
    J Clin Oncol; 2009 Jul; 27(19):3198-204. PubMed ID: 19451432
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effect of the detection of minimal residual disease for the prognosis and the choice of post-remission therapy of intermediate-risk acute myeloid leukemia without FLT3-ITD, NPM1 and biallelic CEBPA mutations.
    Zheng WS; Hu YL; Guan LX; Peng B; Wang SY
    Hematology; 2021 Dec; 26(1):179-185. PubMed ID: 33594943
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia.
    Schlenk RF; Döhner K; Krauter J; Fröhling S; Corbacioglu A; Bullinger L; Habdank M; Späth D; Morgan M; Benner A; Schlegelberger B; Heil G; Ganser A; Döhner H;
    N Engl J Med; 2008 May; 358(18):1909-18. PubMed ID: 18450602
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic significance of CEBPA mutations in a large cohort of younger adult patients with acute myeloid leukemia: impact of double CEBPA mutations and the interaction with FLT3 and NPM1 mutations.
    Green CL; Koo KK; Hills RK; Burnett AK; Linch DC; Gale RE
    J Clin Oncol; 2010 Jun; 28(16):2739-47. PubMed ID: 20439648
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic significance of combined BAALC and MN1 gene expression level in acute myeloid leukemia with normal karyotype.
    Marjanovic I; Karan-Djurasevic T; Kostic T; Virijevic M; Vukovic NS; Pavlovic S; Tosic N
    Int J Lab Hematol; 2021 Jun; 43(3):433-440. PubMed ID: 33242229
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostically important molecular markers in cytogenetically normal acute myeloid leukemia.
    Lin TL; Smith BD
    Am J Med Sci; 2011 May; 341(5):404-8. PubMed ID: 21522052
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic implications of gene mutations in acute myeloid leukemia with normal cytogenetics.
    Gaidzik V; Döhner K
    Semin Oncol; 2008 Aug; 35(4):346-55. PubMed ID: 18692685
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hyperleukocytosis is associated with distinct genetic alterations and is an independent poor-risk factor in de novo acute myeloid leukemia patients.
    Tien FM; Hou HA; Tsai CH; Tang JL; Chen CY; Kuo YY; Li CC; Lin CT; Yao M; Huang SY; Ko BS; Hsu SC; Wu SJ; Tsay W; Tseng MH; Liu MC; Liu CW; Lin LI; Chou WC; Tien HF
    Eur J Haematol; 2018 Jul; 101(1):86-94. PubMed ID: 29624746
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Acute myeloid leukemia with biallelic CEBPA gene mutations and normal karyotype represents a distinct genetic entity associated with a favorable clinical outcome.
    Dufour A; Schneider F; Metzeler KH; Hoster E; Schneider S; Zellmeier E; Benthaus T; Sauerland MC; Berdel WE; Büchner T; Wörmann B; Braess J; Hiddemann W; Bohlander SK; Spiekermann K
    J Clin Oncol; 2010 Feb; 28(4):570-7. PubMed ID: 20038735
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk assessment in patients with acute myeloid leukemia and a normal karyotype.
    Bienz M; Ludwig M; Leibundgut EO; Mueller BU; Ratschiller D; Solenthaler M; Fey MF; Pabst T
    Clin Cancer Res; 2005 Feb; 11(4):1416-24. PubMed ID: 15746041
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular heterogeneity and prognostic biomarkers in adults with acute myeloid leukemia and normal cytogenetics.
    Marcucci G; Mrózek K; Bloomfield CD
    Curr Opin Hematol; 2005 Jan; 12(1):68-75. PubMed ID: 15604894
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Single nucleotide polymorphism in the mutational hotspot of WT1 predicts a favorable outcome in patients with cytogenetically normal acute myeloid leukemia.
    Damm F; Heuser M; Morgan M; Yun H; Grosshennig A; Göhring G; Schlegelberger B; Döhner K; Ottmann O; Lübbert M; Heit W; Kanz L; Schlimok G; Raghavachar A; Fiedler W; Kirchner H; Döhner H; Heil G; Ganser A; Krauter J
    J Clin Oncol; 2010 Feb; 28(4):578-85. PubMed ID: 20038731
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Identification of molecular markers in children with acute myeloid leukemia (AML)].
    Ilenčíková D; Sýkora J; Mikulášová Z; Repiská V
    Klin Onkol; 2012; 25(1):26-35. PubMed ID: 22348217
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Favorable prognostic impact of NPM1 mutations in older patients with cytogenetically normal de novo acute myeloid leukemia and associated gene- and microRNA-expression signatures: a Cancer and Leukemia Group B study.
    Becker H; Marcucci G; Maharry K; Radmacher MD; Mrózek K; Margeson D; Whitman SP; Wu YZ; Schwind S; Paschka P; Powell BL; Carter TH; Kolitz JE; Wetzler M; Carroll AJ; Baer MR; Caligiuri MA; Larson RA; Bloomfield CD
    J Clin Oncol; 2010 Feb; 28(4):596-604. PubMed ID: 20026798
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HOX expression patterns identify a common signature for favorable AML.
    Andreeff M; Ruvolo V; Gadgil S; Zeng C; Coombes K; Chen W; Kornblau S; Barón AE; Drabkin HA
    Leukemia; 2008 Nov; 22(11):2041-7. PubMed ID: 18668134
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Acute myeloid leukemia with normal cytogenetics.
    Mawad R; Estey EH
    Curr Oncol Rep; 2012 Oct; 14(5):359-68. PubMed ID: 22806102
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Allogeneic stem cell transplantation mitigates the adverse prognostic impact of high diagnostic BAALC and MN1 expression in AML.
    Jentzsch M; Bill M; Grimm J; Brauer D; Backhaus D; Goldmann K; Schulz J; Niederwieser D; Platzbecker U; Schwind S
    Ann Hematol; 2020 Oct; 99(10):2417-2427. PubMed ID: 32862286
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Presence of FLT3-ITD and high BAALC expression are independent prognostic markers in childhood acute myeloid leukemia.
    Staffas A; Kanduri M; Hovland R; Rosenquist R; Ommen HB; Abrahamsson J; Forestier E; Jahnukainen K; Jónsson ÓG; Zeller B; Palle J; Lönnerholm G; Hasle H; Palmqvist L; Ehrencrona H;
    Blood; 2011 Nov; 118(22):5905-13. PubMed ID: 21967978
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.